How Ly6 proteins affect chronic pain
Lymphocyte Antigen 6 (Ly6) Proteins: New Players in Chronic Pain
This research explores whether Ly6 proteins change a key pain channel (NaV1.7) and make nerves more or less sensitive, which could point to new treatments for chronic pain.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-10973785 on NIH RePORTER |
What this research studies
You would be hearing about lab work that focuses on proteins called Ly6 that sit outside nerve cells and may change how the NaV1.7 pain channel works. The team will use molecular experiments, genetic tools, mouse models, and human gene-expression data to see whether changing Ly6 levels alters nerve activity and pain-related behavior. They will map how Ly6 proteins interact with NaV1.7 and test whether blocking or boosting Ly6 shifts pain signals. The goal is to find ways to target these extracellular proteins that could lead to new therapies for chronic nerve pain.
Who could benefit from this research
Good fit: Adults with chronic neuropathic pain (for example after nerve injury) would be the most likely group to benefit from therapies developed from this work.
Not a fit: People with short-term acute pain or pain driven mainly by non-neuronal inflammation may not see direct benefit from findings that target NaV1.7 regulation.
Why it matters
Potential benefit: If successful, this work could point to new drug targets that reduce NaV1.7 activity and help lessen chronic neuropathic pain.
How similar studies have performed: Previous research has established NaV1.7 as a key pain molecule and some NaV1.7-targeting approaches have shown promise, but using Ly6 proteins to control NaV1.7 is a newer, less-tested approach.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Gomez, Kimberly — Texas A&m University Health Science Ctr
- Study coordinator: Gomez, Kimberly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.